162 related articles for article (PubMed ID: 37962325)
1. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
2. Etranacogene Dezaparvovec: First Approval.
Heo YA
Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
[TBL] [Abstract][Full Text] [Related]
5. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
6. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
[TBL] [Abstract][Full Text] [Related]
7. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
[TBL] [Abstract][Full Text] [Related]
8. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
9. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
[TBL] [Abstract][Full Text] [Related]
10. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
[TBL] [Abstract][Full Text] [Related]
11. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec.
Anguela XM; High KA
Blood Adv; 2024 Apr; 8(7):1796-1803. PubMed ID: 38592711
[TBL] [Abstract][Full Text] [Related]
13. Hemophilia Gene Therapy: The End of the Beginning?
De Wolf D; Singh K; Chuah MK; VandenDriessche T
Hum Gene Ther; 2023 Sep; 34(17-18):782-792. PubMed ID: 37672530
[TBL] [Abstract][Full Text] [Related]
14. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for hemophilia.
Nathwani AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):569-578. PubMed ID: 36485127
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia.
Thornburg CD; Simmons DH; von Drygalski A
BioDrugs; 2023 Sep; 37(5):595-606. PubMed ID: 37490225
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Miesbach W; Meijer K; Coppens M; Kampmann P; Klamroth R; Schutgens R; Tangelder M; Castaman G; Schwäble J; Bonig H; Seifried E; Cattaneo F; Meyer C; Leebeek FWG
Blood; 2018 Mar; 131(9):1022-1031. PubMed ID: 29246900
[TBL] [Abstract][Full Text] [Related]
18. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
19. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
Itzler R; Buckner TW; Leebeek FWG; Miller J; Recht M; Drelich D; Monahan PE; Pipe SW
Haemophilia; 2024 May; 30(3):709-719. PubMed ID: 38462823
[TBL] [Abstract][Full Text] [Related]
20. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
